EUVIMEDEUVIMED entdecken
Crossref

Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates

Kazuma Nakashima, Hiroyuki Watanabe iD, Masahiro Ono iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c00472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Kazuma Nakashima und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Ky…. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chelator-containing radioimmunoconjugates (RICs) composed of monoclonal antibodies, chelators, and radiometals exhibit broad potential for cancer diagnosis or therapy. In this study, we developed novel trifunctional chelating agents that enhance the tumor retention of RICs, MDPEI2, and MDPEI4, which contain the metal chelator DOTA, a maleimide moiety, and diethylenetriamine (PEI2) or tetraethylenepentamine (PEI4), respectively, as a poly(ethylenimine) (PEI) scaffold for the addition of positive charges to the radiometabolites of RICs to reduce their release from tumor cells. Trastuzumab radiolabeled by [111In]In-MDPEI2 ([111In]In-TMDPEI2) or [111In]In-MDPEI4 ([111In]In-TMDPEI4) showed high immunoreactivity and lower rates of exportations of their radiometabolites from tumor cells than RICs without PEI scaffolds. The tumor uptake of [111In]In-TMDPEI2 and [111In]In-TMDPEI4 was enhanced compared with RICs without PEI scaffolds, and [111In]In-TMDPEI2 exhibited the highest tumor/blood ratio. These results indicate the utility of MDPEI2 to synthesize RICs with favorable tumor-targeting properties in vivo by controlling the radioactivity distribution in tumor cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesNeoplasmsHumansChelating AgentsAntibodies, MonoclonalTrastuzumabCell Line, Tumor

Substanzen

Chelating AgentsImmunoconjugatesAntibodies, MonoclonalTrastuzumab

Autor:innen und Institutionen

  • Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan.

ORCID-Profile: Hiroyuki Watanabe, Masahiro Ono

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Nakashima, K., Watanabe, H., & Ono, M. (2023). Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00472

Vancouver

Nakashima K, Watanabe H, Ono M. Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00472

BibTeX
@article{Nakashima2023,
  author = {Nakashima, Kazuma and Watanabe, Hiroyuki and Ono, Masahiro},
  title = {Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c00472}
}
Kostenlos starten →